5月29日,NMPA官网显示,恒瑞医药的注射用瑞康曲妥珠单抗(SHR-A1811)在国内获批上市,单药适用于治疗存在HER2(ERBB2)激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者。此外,百济神州HER2双抗泽尼达妥单抗(zanidatamab)上市申请也已获批准。2023年11月,该产品被纳入优先审评,适应症为治疗既往接受过全身治疗的...
Source Link5月29日,NMPA官网显示,恒瑞医药的注射用瑞康曲妥珠单抗(SHR-A1811)在国内获批上市,单药适用于治疗存在HER2(ERBB2)激活突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者。此外,百济神州HER2双抗泽尼达妥单抗(zanidatamab)上市申请也已获批准。2023年11月,该产品被纳入优先审评,适应症为治疗既往接受过全身治疗的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.